Literature DB >> 23907761

Haloperidol for severe anorexia nervosa restricting type with delusional body image disturbance: a nine-case chart review.

Mauro Mauri1, Mario Miniati, Michela Giorgi Mariani, Agnese Ciberti, Liliana Dell'Osso.   

Abstract

Here we report on a case series chart review conducted on nine severe and treatment-resistant patients with anorexia nervosa, body mass index < 13 kg/m(2), and a delusional body image disturbance. Patients received low doses of haloperidol during hospitalization. Haloperidol was well tolerated. The delusional body image disturbance and the drive for thinness were subjectively perceived as less intense. BMI increased from the initial 12.2 ± 0.5 to 16.0 ± 1.5 kg/m(2). Mean pulse rate and blood pressure did not change significantly from admission to discharge (66 ± 11.6 bpm; 91/56 mmHg vs 77 ± 12.0 bpm; 102/66 mmHg). Mean of QTc, available from electrocardiograms performed during hospitalization, was 413 ± 38.5 ms (range 342-469 ms). Further investigations are warranted to elucidate clinical usefulness and safety of low doses of haloperidol for patients with treatment-resistant anorexia and delusional body image disturbance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23907761     DOI: 10.1007/s40519-013-0052-9

Source DB:  PubMed          Journal:  Eat Weight Disord        ISSN: 1124-4909            Impact factor:   4.652


  4 in total

1.  Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report.

Authors:  Giovanni B Cassano; Mario Miniati; Stefano Pini; Alessandro Rotondo; Susanna Banti; Chiara Borri; Valeria Camilleri; Mauro Mauri
Journal:  Int J Eat Disord       Date:  2003-03       Impact factor: 4.861

2.  Characteristics of eating disorder patients without a drive for thinness.

Authors:  Carla E Ramacciotti; Liliana Dell'Osso; Riccardo A Paoli; Antonio Ciapparelli; Elisabetta Coli; Allan S Kaplan; Paul E Garfinkel
Journal:  Int J Eat Disord       Date:  2002-09       Impact factor: 4.861

Review 3.  The effect of atypical antipsychotic medications in individuals with anorexia nervosa: a systematic review and meta-analysis.

Authors:  Jocelyn Lebow; Leslie A Sim; Patricia J Erwin; M Hassan Murad
Journal:  Int J Eat Disord       Date:  2012-09-24       Impact factor: 4.861

4.  Epigenetic dysregulation of dopaminergic genes in eating disorders.

Authors:  Helge Frieling; Konstanze D Römer; Sarah Scholz; Franziska Mittelbach; Julia Wilhelm; Martina De Zwaan; Georg E Jacoby; Johannes Kornhuber; Thomas Hillemacher; Stefan Bleich
Journal:  Int J Eat Disord       Date:  2010-11-01       Impact factor: 4.861

  4 in total
  3 in total

Review 1.  The Role of Psychotropic Medications in the Management of Anorexia Nervosa: Rationale, Evidence and Future Prospects.

Authors:  Guido K W Frank; Megan E Shott
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

2.  Mood spectrum comorbidity in patients with anorexia and bulimia nervosa.

Authors:  Mario Miniati; Antonella Benvenuti; Elena Bologna; Alessandra Maglio; Biagio Cotugno; Gabriele Massimetti; Simona Calugi; Mauro Mauri; Liliana Dell'Osso
Journal:  Eat Weight Disord       Date:  2016-10-20       Impact factor: 4.652

3.  Adjunctive Clotiapine for the Management of Delusions in Two Adolescents with Anorexia Nervosa.

Authors:  Jacopo Pruccoli; Giulia Joy Leone; Cristina Di Sarno; Luigi Vetri; Giuseppe Quatrosi; Michele Roccella; Antonia Parmeggiani
Journal:  Behav Sci (Basel)       Date:  2021-12-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.